October 23, 2017
…to chronic inflammation and cancer. Through large-scale genomic analyses, they discovered that “mutant p53” amplifies the impact of inflammation, leading to increases in cancer. Thus, rather than fighting tumor growth, mutant forms of p53 appear to be tapping into the body’s immune response system to fuel pro-inflammatory responses that increase…
September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
September 28, 2015
…reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute (NCI), part of the National Institutes of Health. The five-year grant renews funding for a partnership started in 2008 between San…
June 4, 2024
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
July 2, 2019
Bladder cancer, one of the most common cancers in the U.S., may be soon helped by a novel non-invasive diagnostic method thanks to machine learning research by researchers at UC San Diego’s San Diego Supercomputer Center and Moores Cancer Center.
June 15, 2022
The science behind predicting your viewing habits on Netflix could one day be used to guide doctors in managing some of the hardest-to-treat cancers, shows a study led by the University of California San Diego and University College London.
December 10, 2020
…cells) to destroy his cancer. New Personalized Immunotherapy Trial Launched Despite COVID-19 Pandemic First patient to receive individualized TIL therapy undergoes treatment at Moores Cancer Center Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing successfully eradicated the disease.…
July 2, 2014
Researchers at the University of California, San Diego School of Medicine say a protein essential to regulating cell cycle progression – the process of cell division and replication – activates a key tumor suppressor, rather than inactivating it as previously thought.
November 24, 2021
The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
May 21, 2014
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have used computer simulations of cancer cells – cancer avatars – to identify drugs most likely to kill cancer cells isolated from patients’ brain tumors.
